You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction

    SBC: PHENVOGEN LLC            Topic: 300

    PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Oligonucleotide Inhibition for cardiac regeneration in Ischemia

    SBC: JAAN BIOTHERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration of heart function compromise of contractile reserve ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A novel anti gonorrhea immunotherapeutic

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment

    SBC: ZYMO RESEARCH CORP.            Topic: 101

    PROJECT SUMMARY ABSTRACT Stroke injury is a process that occurs over a long duration with pathologic changes that result in long term neurologic dysfunction For stroke there exists an important need for a strategy that can provide safe and efficacious stabilization to the hypoperfused brain and initialize long lasting endogenous neuroprotection for prevention of long term neurologic dysfunction ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Automated electrophysiological analysis of neural circuitry using a novel nano electrode array for intracellular recording of membrane potential

    SBC: CYION TECHNOLOGIES LLC            Topic: 101

    Summary Nervous systems process information by integrating the electrical activity of neurons in complex networks The alterations in the flow of electrical activity through neuronal networks of the brain play a causal role in the pathogenesis and or the appearance of symptoms of neurodegenerative and psychiatric diseases A fundamental goal of BRAIN Initiative is therefore to elucidate how the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Gold nanoparticle laser warming of cryopreserved zebrafish embryos

    SBC: NANOCOMPOSIX, INC.            Topic: OD

    Project Summary Abstract In the past decade laboratories around the world have produced tens of thousands of mutant transgenic and wild type zebrafish lines for a wide range of genetic and biomedical research Maintaining all of these valuable genotypes is expensive risky and beyond the capacity of even the largest stock centers Cryopreservation of zebrafish sperm eggs and embryos is vital ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Next Generation Regenerative Therapy with Pim Enhanced Cardiac Progenitor Cells

    SBC: CardioCreate, Inc.            Topic: NHLBI

    PROJECT SUMMARY Myocardial regenerative therapy is poised to revolutionize the way heart failure is treated but further improvements and enhanced products are needed to make this therapy truly safe and efficacious Our company CardioCreate Inc has pioneered the use of genetic engineering to enhance the regenerative potential of human Cardiac Progenitor Cells CPCs intended for autologous the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government